KAT6A::EP300 fusion in congenital myeloid sarcoma: Yet another novel molecular marker indicating spontaneous remission?: A case report

Acute myeloid leukemia (AML)/myeloid sarcoma (MS) is risk-stratified based on cytogenetics. Although most congenital AML/MS have a dismal prognosis, certain genetic variants such as t (8, 16) [KAT6A::cAMP response element-binding protein (CREB) - binding protein fusion] and more recently t (8, 22) [...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosahalli Vasanna, Smitha, Shah, Sonal D., Rohr, Bethany R., Roche, Breanne, Meyerson, Howard, Pateva, Irina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Research Article: Clinical Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378725/
https://www.ncbi.nlm.nih.gov/pubmed/37505185
http://dx.doi.org/10.1097/MD.0000000000034258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378725/
https://www.ncbi.nlm.nih.gov/pubmed/37505185
http://dx.doi.org/10.1097/MD.0000000000034258

Ejemplares similares